golimumab
janssen,merck
['axspa']
#abstr 0545 go-back trial
continue vs withdrawal of gol in nr-axspa with inactive disease
- full tx withdrawal associated w/ dx flare - re-treatment --&gt;rapid clinical response after flare
- qmonthly tx --&gt; higher rates of disease activity improvement #acr22 
Immunology & Rheumatology Fellow @StanfordMed| IM Residency @UTMBHealth |@McGovernMed & @EmoryUniversity Alum | Tweets are my own